A Phase I/II Study of Sorafenib and Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer.
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Liver cancer; Pancreatic cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 12 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Feb 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 15 Apr 2010 Primary outcome amended as reported by ClinicalTrials.gov.